CRBP - Rasio rega marang prakiraan pendapatan Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals, Inc. (CRBP) - logo korporat

Corbus Pharmaceuticals relies on the ultra-precise CRB-701 conjugate to combat cancer, ensuring significant pricing power. Market capitalization is based on inflammation-related patents and partnerships with pharmaceutical behemoths. Positive trial results against solid tumors create the primary growth momentum. The forward P/S valuation history visualizes the dynamics of market expectations, while 69.50 captures the current value of the indicator.

Corbus Pharmaceuticals Holdings, Inc. - Prakiraan rega marang pendapatan CRBP (periode 04.07.2022 - 13.11.2022)

Rincian metrik komprehensif lan analitis Corbus Pharmaceuticals Holdings (CRBP)

- rega pasar lan target rega analis:
Analisis umum perusahaan:Corbus Pharma CRBP
Produk sing diprodhuksi corbuspharma.com

The monopoly potential of the Corbus Pharmaceuticals (CRBP) patent portfolio in the treatment of rare oncological diseases allows the company to build in high margins as it scales production. This forward price-to-sales valuation trend compares current market capitalization with expected annual sales amid tight monetary policy, where rising values signal inflated market expectations and the risk of overpaying for future success.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Incyte Corp. INCY|HUTCHMED Ltd (HCM) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|NUVB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Day One|MNPR: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Inhibrx Biosciences Inc INBX|Multiplikator forward rega marang pendapatan IMAB|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Fennec Pharmaceuticals FENC|Multiplikator forward rega marang pendapatan HRTX (Heron)|NVCT (Nuvectis Pharma) - Rega forward marang dodolan|Coherus Biosciences - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CRDF (Cardiff Oncology Corp)|BeyondSpring Pharma - Multiplikator Forward P/S|Rega forward marang dodolan BCAB (bioatla.com)|LIXT: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Citius Pharma (CTXR)|Rasio rega marang prakiraan pendapatan Cellectar Biosciences, Inc.|BLRX: Rega forward marang dodolan|Multiplikator Forward P/S CANF|Multiplikator Forward P/S Aprea Therapeutics Inc. (APRE)|Rasio rega marang prakiraan pendapatan Kazia Therapeutics Ltd KZIA|SLXN (silexion.com) - Rega mangsa ngarep marang pendapatan|NCNA: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Chimerix|CYCC: Multiplikator Forward P/S|Prakiraan rega marang pendapatan G1 Therapeutics Inc. GTHX|Rasio rega marang prakiraan pendapatan Kronos Bio, Inc.|kintara.com (KTRA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S ONCT|PRTG (Portage) - Rega forward marang dodolan